Numerous therapies are currently available to modify the disease course of multiple
sclerosis (MS). Magnetic resonance imaging (MRI) plays a pivotal role in assessing …

Cladribine tablets have been granted marketing authorization in Europe and approved by
the Food and Drug Administration (FDA) in the USA to treat relapsing forms of multiple …

Cladribine tablets (Mavenclad®) were approved by the European Union in 2017 as high-
efficacy therapy for highly active relapsing–remitting multiple sclerosis. In Israel …

Based on the results of the pivotal CLARITY study, cladribine tablets were approved for use
in the European Union in 2017 as a high-efficacy therapy for highly active relapsing …

The number of ageing people with relapsing multiple sclerosis (RMS) is increasing. The
efficacy of disease-modifying therapies (DMTs) for RMS declines with age. Also, older …

Multiple sclerosis (MS) is a chronic autoimmune neurological disorder that significantly
impacts the central nervous system (CNS), which includes the brain and spinal cord …

Cladribine tablets (CladT) has been available for therapeutic use in France since March
2021 for the management of highly active relapsing multiple sclerosis (RMS). This high …

Abstract Objective In Iraq, a lack of evidence-based management protocols for diagnosing,
treating, and managing multiple sclerosis (MS) poses risks of suboptimal outcomes and …

Background The current approval of oral cladribine covers four years, with two treatment
courses in the first two years, followed by two treatment-free years. For decision-making in …

Multiple sclerosis (MS) is a chronic disease whose pathogenesis is based on autoimmune
neuroinflammatory and neurodegenerative components. The goal of therapy of MS is to …